ATE269700T1 - Verwendung von docetaxel für die behandlung von hepatozelluläre krebs - Google Patents

Verwendung von docetaxel für die behandlung von hepatozelluläre krebs

Info

Publication number
ATE269700T1
ATE269700T1 AT00964144T AT00964144T ATE269700T1 AT E269700 T1 ATE269700 T1 AT E269700T1 AT 00964144 T AT00964144 T AT 00964144T AT 00964144 T AT00964144 T AT 00964144T AT E269700 T1 ATE269700 T1 AT E269700T1
Authority
AT
Austria
Prior art keywords
docetaxel
treatment
hepatocellular cancer
hepatocellular carcinoma
mum
Prior art date
Application number
AT00964144T
Other languages
English (en)
Inventor
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Lui
Gar-Yang Chau
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE269700T1 publication Critical patent/ATE269700T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT00964144T 1999-08-31 2000-08-29 Verwendung von docetaxel für die behandlung von hepatozelluläre krebs ATE269700T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
ATE269700T1 true ATE269700T1 (de) 2004-07-15

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964144T ATE269700T1 (de) 1999-08-31 2000-08-29 Verwendung von docetaxel für die behandlung von hepatozelluläre krebs

Country Status (34)

Country Link
US (2) US20030158249A1 (de)
EP (1) EP1214061B1 (de)
JP (1) JP4866522B2 (de)
KR (1) KR100670416B1 (de)
CN (1) CN1174748C (de)
AT (1) ATE269700T1 (de)
AU (1) AU777583B2 (de)
BG (1) BG65913B1 (de)
BR (1) BR0013625A (de)
CA (1) CA2382294C (de)
CZ (1) CZ301378B6 (de)
DE (1) DE60011794T2 (de)
DK (1) DK1214061T3 (de)
EA (1) EA004804B1 (de)
EE (1) EE05124B1 (de)
ES (1) ES2218223T3 (de)
GB (1) GB9920548D0 (de)
HK (1) HK1048944B (de)
HR (1) HRP20020171A2 (de)
HU (1) HU228861B1 (de)
IL (2) IL147489A0 (de)
ME (1) MEP7809A (de)
MX (1) MXPA02002041A (de)
NO (1) NO328527B1 (de)
NZ (1) NZ517604A (de)
PL (1) PL212612B1 (de)
PT (1) PT1214061E (de)
RS (1) RS50148B (de)
SI (1) SI1214061T1 (de)
SK (1) SK286378B6 (de)
TW (1) TW589180B (de)
UA (1) UA72927C2 (de)
WO (1) WO2001015675A2 (de)
ZA (1) ZA200201408B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
EP1947094A3 (de) * 2003-12-12 2009-02-18 Quiral Quimica Do Brasil Herstellungsverfahren für Taxanderivate
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
LT3311805T (lt) * 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3527202A1 (de) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Zusammensetzungen und verfahren zur herstellung schwer wasserlöslicher arzneimittel mit erhöhter stabilität
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20080262078A1 (en) * 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
US10842770B2 (en) * 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US6544979B1 (en) * 1997-09-18 2003-04-08 Janssen Pharmaceuticals, N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents
EP1027045A4 (de) * 1997-10-31 2004-12-08 Arch Dev Corp Methoden und zusammenstellungen zur regelierung des s-alpha-reduktaseaktivität
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU2592600A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
US8080672B2 (en) * 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof

Also Published As

Publication number Publication date
BG106460A (bg) 2002-09-30
JP2003508427A (ja) 2003-03-04
HK1048944B (zh) 2005-04-22
US20030158249A1 (en) 2003-08-21
NO20020829L (no) 2002-02-20
BG65913B1 (bg) 2010-05-31
ZA200201408B (en) 2003-07-30
PL212612B1 (pl) 2012-10-31
TW589180B (en) 2004-06-01
US20080045584A1 (en) 2008-02-21
RS50148B (sr) 2009-05-06
ME00624B (me) 2011-12-20
DE60011794D1 (de) 2004-07-29
MEP7809A (en) 2011-12-20
YU11402A (sh) 2005-07-19
DE60011794T2 (de) 2005-07-14
HUP0203197A2 (hu) 2003-01-28
ES2218223T3 (es) 2004-11-16
CZ301378B6 (cs) 2010-02-03
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
JP4866522B2 (ja) 2012-02-01
BR0013625A (pt) 2002-05-14
EE200200087A (et) 2003-04-15
MXPA02002041A (es) 2002-08-20
CN1372466A (zh) 2002-10-02
SI1214061T1 (en) 2004-12-31
HU228861B1 (hu) 2013-06-28
SK286378B6 (sk) 2008-08-05
HK1048944A1 (en) 2003-04-25
AU7516800A (en) 2001-03-26
NZ517604A (en) 2004-04-30
HRP20020171A2 (en) 2004-02-29
NO328527B1 (no) 2010-03-08
IL147489A0 (en) 2002-08-14
CA2382294A1 (en) 2001-03-08
UA72927C2 (uk) 2005-05-16
SK2712002A3 (en) 2002-07-02
EE05124B1 (et) 2009-02-16
EP1214061B1 (de) 2004-06-23
KR20020060166A (ko) 2002-07-16
EA200200313A1 (ru) 2002-08-29
PT1214061E (pt) 2004-09-30
CA2382294C (en) 2008-06-03
IL147489A (en) 2006-06-11
HUP0203197A3 (en) 2005-01-28
DK1214061T3 (da) 2004-11-01
EP1214061A2 (de) 2002-06-19
GB9920548D0 (en) 1999-11-03
WO2001015675A2 (en) 2001-03-08
KR100670416B1 (ko) 2007-01-17
CN1174748C (zh) 2004-11-10
PL353198A1 (en) 2003-11-03
WO2001015675A3 (en) 2001-09-20
NO20020829D0 (no) 2002-02-20
AU777583B2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE269700T1 (de) Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
ATE408601T1 (de) Fredericamycin-derivate
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
GB0223038D0 (en) Therapeutic compounds
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
NO20050640L (no) Rutenium anticancer komplekser
NO20032406L (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
IS2849B (is) Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting
DK1244614T3 (da) Tryptase-inhibitorer
SE0301885D0 (sv) New use IV
DE60111614D1 (de) Taxan-derivate für die behandlung von krebs
DE50010972D1 (de) UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN
BRPI0407681A (pt) sulfamatos de d-homoestra-1,3,5(10)-trien-3-ila 2-substituìdos ativos antitumorais
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
TR200401036T1 (tr) Yüksek kan basıncının tedavisi için citalopram.
DE50211837D1 (de) Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren
ATE293107T1 (de) Luminacine analoge und deren verwendung
DE10342747A1 (de) Pharmazeutischer Wirkstoff gegen Melanome
TW200505836A (en) Cyclic sulfonamides for inhibition of gamma-secretase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1214061

Country of ref document: EP